Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Greater Austin Allergy | UNKNOWN |
| Evidera, Inc. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.
AstraZeneca has developed the AMAZE™ disease management platform to be used across multiple disease indications to provide a unified experience for the management of patients throughout their patient care journey. AMAZE™ integrates multiple systems, including a patient mobile application where patients can enter daily symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials. Implementation of AMAZE™ within clinical practice has not yet been evaluated. The results from this study will be used to inform any changes or modifications that need to be made to the technology platform, its implementation process, and explore impact on clinical outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Quality Initiative | Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and GAA clinical staff. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AMAZE™ Disease Management Platform | Device | The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app. |
| Measure | Description | Time Frame |
|---|---|---|
| Patient App Usage | Patient app usage will be measured as the number of days the patient engages (i.e., completes daily log, sends a message) with the app at least once a day during the study period. | Up to 6 months |
| Clinician Dashboard Usage | Clinician dashboard usage will be measured as the mean number of days per week/month that the clinical site staff accessed the AMAZE™ dashboard over the 6-month period. | Up to 6 months |
| Daily Asthma status | Patient daily asthma status (bad, okay, good) reported on the app will be described weekly during Month 1, and then per month from Month 1 through Month 6 pending availability of data after Month 1. | Up to 6 months |
| Symptoms and Triggers | Frequency of symptoms and frequency of triggers (for those that reported symptoms) reported on the app will be described weekly during Months 1, and then per month from Month 1 through Month 6 pending availability of data after Month 1. | Up to 6 months |
| Self-Reported Rescue Medication usage | The number of times per month a patient used rescue medication as well as visited the emergency room or urgent care as reported on the app will be described from Month 1 through Month 6. | Up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Impact of AMAZE™ on patient visits | The impact of AMAZE™ on patient visits will be measured as the frequency of patients who select "agree" or "strongly agree" in response to the 9-items in the patient visit experience survey. | Up to 6 months |
| ER visits and Hospitalization avoidance |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluating change in medication | Medication changes from baseline to six-month will be evaluated. | Up to 6 months |
| Evaluating clinician-reported asthma control | Asthma control was assessed by a clinician completed single item; asthma control at baseline will be evaluated. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants will be recruited from the GAA network, with approximately 120 patients ≥18 years old with a current diagnosis of asthma being enrolled. Participants will need to have access to a smartphone with internet.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eric Schultz, DO, MPH | GAA | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Austin | Texas | 78730 | United States | ||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39479373 | Derived | Alladina J, Moschovis PP, Gandhi HN, Carstens D, Bacci ED, Cutts K, Coyne KS, Goldsborough K, Jiang D, O'Brien C, Bernard Kinane T. Observational study of the Amaze asthma disease management platform. Digit Health. 2024 Oct 22;10:20552076241282380. doi: 10.1177/20552076241282380. eCollection 2024 Jan-Dec. |
| Label | URL |
|---|---|
| Redacted CSR synopsis | View source |
Not provided
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Not provided
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
The impact of AMAZE™ on ER and hospitalizations will be measured as the frequency of patients who report "agree" or "strongly agree" with the item "The visit helped avoid an ER or Urgent Care center visit or hospitalization" from the patient visit experience survey |
| Up to 6 months |
| Patient Perception of Appointment Discussions and Taking Part in Asthma Decisions | The impact of AMAZE™ on improved patient communication with their provider will be measured as the frequency of patients who report "agree" or "strongly agree" with the items "the app helped me discuss my asthma with my healthcare provider(s) during my most recent visit" and "I was included in making decisions about my asthma treatment during my most recent visit" on the patient visit experience survey. | Up to 6 months |
| Patient Perception of Usability and Design of Mobile app | The usability of the AMAZE™ app will be measured by the frequency of patients who rate the app excellent (SUS score >80.3), good (68-80.3), okay (68), poor (51-68), or awful (<51) at months 1 and 6 | Up to 6 months |
| Clinical Staff Perception of Usability and Design of Dashboard | The usability of the AMAZE™ dashboard will be measured by the frequency of clinical staff who rate the app excellent (SUS score >80.3), good (68-80.3), okay (68), poor (51-68), or awful (<51) at months 1 and 6 | Up to 6 months |
| Evaluate ease of implementation of AMAZE™ in clinical setting | The ease of implementation of AMAZE™ will be measured by the frequency of clinical staff who report "very easy" or "somewhat easy" to the question "How would you rate the overall ease of implementing AMAZE™ on a platform into your clinical practice?" in the post-study survey at month 6. | Up to 6 months |
| Evaluate impact of AMAZE™ on managing patients | The impact of AMAZE™ on managing patients will be measured by the frequency of clinical staff who report "moderately" or "very well" to the question "Did the AMAZE™ help you manage your patients?" in the post-study survey at month 6. | Up to 6 months |
| Evaluate Perceived Benefit of AMAZE™ in clinical setting | The perceived benefit of AMAZE™ will be evaluated by the frequency of clinical staff who endorse different perceived benefits based on the item "what did you find the most useful about the AMAZE™ platform?" in the post-study survey at month 6. | Up to 6 months |
| Evaluate Perceived Disadvantages of AMAZE™ in clinical setting | The perceived disadvantages of AMAZE™ will be evaluated by the frequency of clinical staff who endorse different perceived disadvantages based on the item "what did you find the least useful or cumbersome about the AMAZE™ platform?" in the post-study survey at month 6. | Up to 6 months |
| Evaluate patient satisfaction with healthcare experience | Patient satisfaction with their healthcare experience will be evaluated using the PSQ-18 items and subscale scores (General Satisfaction, Technical Quality, Interpersonal Manner, Communication, Financial Aspects, Time Spent with Doctor, Accessibility and Convenience) at Month 6. | Up to 6 months |
| Evaluate patient satisfaction with app | Satisfaction with the app features will be measured by the frequency of patients who report satisfaction on a scale of 1 (lowest satisfaction) to 5 (highest satisfaction) at months 1, 3, and 6. | Up to 6 months |
| Up to 6 months |
| Evaluating patient-reported asthma control | The impact of AMAZE™ on asthma control will be measured as the frequency of patients considered to be poorly controlled (ACT scores ≤15), not well-controlled (ACT scores 16-19, and well-controlled (ACT scores ≥20) from Month 1 through Month 6. | Up to 6 months |
| Changes in asthma symptoms before clinical visit | Frequency of symptoms reported in the patient daily log up to a week proceeding a clinical visit during the study period will be evaluated to assess trends in symptoms that may have triggered a visit. | Up to 6 months |
| Changes in medication after clinical visit | Following a clinical visit any time during the study period, medication changes will be monitored to determine if any changes were prompted by the visit. | Up to 6 months |
| Characteristics of Patients Most Likely to Benefit from AMAZE™ | Demographic information reported by the patient and clinical information reported by the clinical staff will be used and stratified by subgroups, including age, asthma severity, education, and ethnicity, to evaluate characteristics of patients most likely to benefit from AMAZE™ | Up to 6 months |
| Austin |
| Texas |
| 78746 |
| United States |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |